title: A case of aminoglycosides induced retinal toxicity treated with megadoses of steroids and an intravitreal dexamethasone implant (Ozurdex(®)).
abstract: METHODS
  The case is described of a patient who had a sudden loss of vision in her right eye after glaucoma surgery. A diagnosis of retinal toxicity due to tobramycin (an aminoglycoside) was reached, which was characterised by retinal whitening with a red cherry stain, macular oedema, and vasculitis that progressed to papillary and macular atrophy with arteriolar sclerosis. Given the severity of symptoms an early attempt was made with megadoses of steroids and an intravitreal dexamethasone implant (Ozurdex®, Allergan S.A.), without response.
  
  
  CONCLUSIONS
  Aminoglycoside toxicity is a rare, idiosyncratic, very serious complication for which there is no effective treatment.
authors.affiliation: Servicio de Oftalmología, Hospital Universitario San Juan Alicante, San Juan de Alicante, Alicante, España. Electronic address: oftalmofer@yahoo.es.
authors.forename: F
authors.initials: F
authors.lastname: Hernández Pardines
authors.affiliation: Servicio de Oftalmología, Hospital Universitario San Juan Alicante, San Juan de Alicante, Alicante, España.
authors.forename: H
authors.initials: H
authors.lastname: Tapia-Quijada
authors.affiliation: Servicio de Oftalmología, Hospital Universitario San Juan Alicante, San Juan de Alicante, Alicante, España.
authors.forename: J R
authors.initials: JR
authors.lastname: Hueso-Abancens
mesh_terms: D060433:Administration, Ophthalmic; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000009:adverse effects; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004343:Drug Implants; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005901:Glaucoma / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D007511:Ischemia / Q000139:chemically induced* / Q000188:drug therapy; D008269:Macular Edema / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000139:chemically induced* / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D031300:Retinal Vasculitis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D014031:Tobramycin / Q000009:adverse effects* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D004343:Drug Implants; D003907:Dexamethasone; D011241:Prednisone; D014031:Tobramycin; D008775:Methylprednisolone
keywords: Aminoglucósidos; Aminoglycosides; Cherry red spot; Cirugía de glaucoma; Glaucoma surgery; Mancha rojo cereza; Occlusive vasculitis; Ozurdex(®) (implante vítreo de dexametasona); Ozurdex(®) (intravitreal dexamethasone implant); Retinal toxicity; Toxicidad retiniana; Vasculitis oclusiva